Cumberland Pharma reports 2023 net loss of $6.3M; revenue $40M; Caldolor labeling expanded to infants

CUMBERLAND PHARMACEUTICALS INC

Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).
Revenue $40M from four brands: Kristalose $16M, Vibativ $8.8M, Sancuso $8.1M, Caldolor $4.3M.
FDA approved expanded Caldolor labeling for infants 3-6 months; only non-opioid injectable for pain/fever in that age group.
NOPAIN Act expected to provide favorable CMS reimbursement for Caldolor starting 2025; company submitted request.
Ifetroban Phase II trials ongoing for DMD, scleroderma, IPF; FDA grants >$1M; oral capsule study initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CUMBERLAND PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-24-009006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.